CTLA4 and clear cell renal carcinoma: This systematic review updated on relative efficacy of different combination therapies (tyrosine kinase inhibitors or monoclonal antibodies blocking the CTLA-4 combined with immune checkpoint inhibitors) for the first-line treatment of metastatic clear-cell renal cell carcinoma.